Q-omics provides the consensus-scored TMEM262 profile across patient tissues and cancer cell-line models. TMEM262 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM262 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TMEM262 RNA expression shows 18,235 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where TMEM262 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM262 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM262 survival associations across molecular data types. TMEM262 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM262 RNA expression–survival associations across cancer types. High TMEM262 expression shows unfavorable associations in KIRC, KICH, ACC, COAD and LIHC, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM262 RNA expression.
This table summarizes TMEM262 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM262. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM262 shows higher tumor expression in HNSC, COAD, KIRC, BLCA, LIHC and KICH. The HNSC box plot shows higher TMEM262 RNA expression in tumor versus normal tissue (log2 FC = +0.207, t-test p < 0.001).
This table shows molecular features associated with TMEM262 in patient tissues and cancer cell lines. In patient samples, TMEM262 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM262 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
